{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-013727","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.770881+00:00","generated_at":"2026-06-12T03:21:44.484271+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51","bullets":["Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.","Diagnostics & Genomics segment organic growth 10% in Q4; full-year 8%.","ExoDx prostate test revenue surged 68% in Q4; GMP proteins up 58%.","Acquired Lunaphore (COMET spatial biology platform) – no deal value disclosed.","Quarterly dividend declared $0.08/share, payable Sept 1, record Aug 18."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-013727","json":"https://secwatch.observer/filing/0001558370-23-013727.json","markdown":"https://secwatch.observer/filing/0001558370-23-013727.md","text":"https://secwatch.observer/filing/0001558370-23-013727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837023013727/0001558370-23-013727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837023013727/tmb-20230808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:21:44.484271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}